News

Medicare hospital-related mortality down since 1999


 

FROM JAMA

References

Several measures of mortality declined among hospitalized Medicare fee-for-service beneficiaries from 1999 to 2013, according to a study published July 28 in JAMA.

Over that time period, in-hospital mortality declined from 1.3% to 0.71%. Meanwhile, 30-day mortality declined from 2.16% in 1999 to 1.65% in 2013 and 1-year mortality slipped from 4.49% to 3.48% among 60,056,069 individuals aged 65 years or older who were enrolled in a Medicare fee-for-service plan for at least 1 month over the study period, reported Dr. Harlan M. Krumholz of Yale University in New Haven, Conn., and his associates.

The decline in mortality was accompanied by a drop in the number of hospitalizations, which went from more than 35,000/100,000 person-years of enrollment in 1999 to just under 27,000 in 2013. The number of beneficiaries admitted to the hospital at least once went down as well, from almost 22,000/100,000 person-years to more than 17,000, as did the number of hospitalizations that involved major surgery: 3,784/100,000 person-years in 1999 and 3,105 in 2013, the investigators noted (JAMA 2015;314:355-65).

For each of these measures, “the findings did not change substantially after accounting for beneficiaries’ demographic characteristics and geographical differences,” they wrote.

Dr. Krumholz is supported by a grant from the National Heart, Lung, and Blood Institute.

rfranki@frontlinemedcom.com

Recommended Reading

Business associate agreements
MDedge Endocrinology
To maintain independent practice, rethink structure, build partnerships
MDedge Endocrinology
Bills emerge to increase birth control access
MDedge Endocrinology
Senators query GAO on healthcare.gov scam report
MDedge Endocrinology
Massachusetts General named top hospital for 2015-2016
MDedge Endocrinology
AMA Town Hall: Doctors call for meaningful use delay
MDedge Endocrinology
Good news, bad news in the Medicare trustees report
MDedge Endocrinology
Study questions whether MOC is worth the time
MDedge Endocrinology
Value-based care poses new legal risks for doctors
MDedge Endocrinology
Drug manufacturers delayed reporting serious unexpected adverse events
MDedge Endocrinology